Black Rock Inc. Jounce Therapeutics, Inc. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.9 - $1.85 $22,650 - $46,558	-25,167 Reduced 0.98%	2,546,289 $4.71 Million
Q4 2022 Feb 13, 2023	SELL	$0.64 - $1.99 $139,429 - $433,539	-217,859 Reduced 7.81%	2,571,456 $2.85 Million
Q3 2022 Nov 14, 2022	BUY	$2.73 - $4.92 $341,228 - $614,960	124,992 Added 4.69%	2,789,315 $6.53 Million
Q2 2022 Aug 12, 2022	BUY	$2.8 - $7.67 $552,902 - $1.51 Million	197,465 Added 8.0%	2,664,323 $8.07 Million
Q1 2022 May 12, 2022	SELL	$6.01 - $8.54 $265,509 - $377,280	-44,178 Reduced 1.76%	2,466,858 $16.8 Million
Q4 2021 Feb 10, 2022	SELL	$7.11 - $9.64 $169,324 - $229,576	-23,815 Reduced 0.94%	2,511,036 $21 Million
Q3 2021 Nov 09, 2021	BUY	$5.04 - $8.73 $391,870 - $678,774	77,752 Added 3.16%	2,534,851 $18.8 Million
Q2 2021 Aug 11, 2021	BUY	$6.58 - $10.66 $16.2 Million - $26.2 Million	2,457,099 New	2,457,099 $16.7 Million

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.